Mortality Risk Factors Among People Living with HIV Receiving Second-line Antiretroviral Therapy in Rural China

  • Authors: Kang Q.1, Pan W.2, Ma Y.3, Wang D.1, Jia H.1, Guo H.4, Sang F.5, Xu L.4, Xu Q.6, Jin Y.4
  • Affiliations:
    1. The First Clinical Medical School, Henan University of Chinese Medicine
    2. The First Clinical Medical Schoo, Henan University of Chinese Medicin
    3. Center for AIDS/STD Control and Prevention, Center for Disease Control and Prevention of Henan Province
    4. Department of Acquired Immune Deficiency Syndrome Treatment and Research Center, First Affiliated Hospital of Henan University of Chinese Medicine
    5. Henan Key Laboratory of Viral Diseases Prevention and Treatment of Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou
    6. The First Clinical Medical School, Henan University of Chinese Medicine,
  • Issue: Vol 22, No 2 (2024)
  • Pages: 100-108
  • Section: Medicine
  • URL: https://clinpractice.ru/1570-162X/article/view/644029
  • DOI: https://doi.org/10.2174/011570162X280721240108065502
  • ID: 644029

Cite item

Full Text

Abstract

Background:Second-line antiretroviral therapy (ART) was introduced in Henan Province in 2009. The number of people living with human immunodeficiency virus (HIV) starting this therapy is increasing.

Objective:This study aimed to investigate the survival and factors affecting mortality among this group.

Methods:We conducted a retrospective cohort study of people living with HIV (PLHIV) who switched to second-line ART between May 1, 2010, and May 1, 2016, using the Kaplan–Meier method and Cox proportional hazards models.

Results:We followed 3,331 PLHIV for 26,988 person-years, of whom 508 (15.3%) died. The mortality rate was 1.88/100 person-years. After adjusting for confounding factors, we found being a woman (hazard ratio (HR), 0.66; 95% confidence interval (CI) 0.55–0.79), > 50 years old (HR, 2.69; 95% CI, 2.03–3.56), single/widowed (HR, 1.26; 95% CI, 1.04–1.52), having > 6 years of education (HR, 0.78; 95% CI, 0.65–0.94), Chinese medicine (HR, 0.75; 95% CI, 0.52–0.96), liver injury (HR, 1.58; 95% CI, 1.19–2.10), and CD4+ T cell counp <000 cells/µl (HR, 1.94; 95% CI, 1.47-2.55), or 200-350 cells/µl (HR, 1.37; 95% CI, 1.03–1.82) were associated with mortality risk.

Conclusions:We found lower mortality among PLHIV who switched to second-line ART than most previous studies. The limitations of a retrospective cohort may, therefore, have biased the data, and prospective studies are needed to confirm the results. Moreover, Chinese medicine combined with second-line ART shows potential as a treatment for HIV.

About the authors

Qiujia Kang

The First Clinical Medical School, Henan University of Chinese Medicine

Email: info@benthamscience.net

Wanqi Pan

The First Clinical Medical Schoo, Henan University of Chinese Medicin

Email: info@benthamscience.net

Yanmin Ma

Center for AIDS/STD Control and Prevention, Center for Disease Control and Prevention of Henan Province

Email: info@benthamscience.net

Dongli Wang

The First Clinical Medical School, Henan University of Chinese Medicine

Email: info@benthamscience.net

Huangchao Jia

The First Clinical Medical School, Henan University of Chinese Medicine

Email: info@benthamscience.net

Huijun Guo

Department of Acquired Immune Deficiency Syndrome Treatment and Research Center, First Affiliated Hospital of Henan University of Chinese Medicine

Email: info@benthamscience.net

Feng Sang

Henan Key Laboratory of Viral Diseases Prevention and Treatment of Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou

Email: info@benthamscience.net

Liran Xu

Department of Acquired Immune Deficiency Syndrome Treatment and Research Center, First Affiliated Hospital of Henan University of Chinese Medicine

Email: info@benthamscience.net

Qianlei Xu

The First Clinical Medical School, Henan University of Chinese Medicine,

Author for correspondence.
Email: info@benthamscience.net

Yantao Jin

Department of Acquired Immune Deficiency Syndrome Treatment and Research Center, First Affiliated Hospital of Henan University of Chinese Medicine

Author for correspondence.
Email: info@benthamscience.net

References

  1. Unaids. Global AIDS update. 2020. Available from: https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf
  2. Barik SK, Bansal AK, Mohanty PS, et al. Detection of drug resistance mutations in the reverse transcriptase gene of hiv-1-infected north indian population failing first-line antiretroviral therapy "a follow-up cohort study". AIDS Res Hum Retroviruses 2021; 37(10): 796-805. doi: 10.1089/aid.2020.0132 PMID: 33390085
  3. Alene M, Awoke T, Yenit MK, Tsegaye AT, Yismaw L, Yeshambel R. Second-line antiretroviral therapy regimen change among adults living with HIV in Amhara region: a multi-centered retrospective follow-up study. BMC Res Notes 2019; 12(1): 407. doi: 10.1186/s13104-019-4429-3 PMID: 31307513
  4. Martinez-Vega R, De La Mata NL, Kumarasamy N, et al. Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE). Antivir Ther 2018; 23(2): 167-78. doi: 10.3851/IMP3194 PMID: 28933705
  5. Sam M, Masaba JPM, Alio D, Byakika-Tusiime J. Treatment failure and associated factors among individuals on second line antiretroviral therapy in Eastern Uganda: A retrospective cohort study. Infect Dis 2021; 14(1786337211014518) doi: 10.1177/11786337211014518 PMID: 34121842
  6. Edessa D, Sisay M, Asefa F. Second-line HIV treatment failure in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One 2019; 14(7): e0220159. doi: 10.1371/journal.pone.0220159 PMID: 31356613
  7. Zenebe Haftu A, Desta AA, Bezabih NM, et al. Incidence and factors associated with treatment failure among HIV infected adolescent and adult patients on second-line antiretroviral therapy in public hospitals of Northern Ethiopia: Multicenter retrospective study. PLoS One 2020; 15(9): e0239191. doi: 10.1371/journal.pone.0239191 PMID: 32986756
  8. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV Infection: Recommendations for a public health approach. 2013. Available from : https://www.who.int/publications/i/item/9789241549684
  9. Development of china free art manual. Available from: http://www.aizhi.org/UploadSoft/2005321103838886.pdf
  10. Gao L, Xia H, Zeng R, et al. Pre-treatment and acquired antiretroviral drug resistance among people living with HIV in Tianjin, China. HIV Med 2022; 23(S1) (Suppl. 1): 84-94. doi: 10.1111/hiv.13252 PMID: 35293099
  11. Chen J, Zhang M, Shang M, Yang W, Wang Z, Shang H. Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China. BMC Infect Dis 2018; 18(1): 571. doi: 10.1186/s12879-018-3489-7 PMID: 30442114
  12. Dou Z, Chen RY, Wang Z, et al. HIV-infected former plasma donors in rural central china: From infection to survival outcomes, 1985-2008. PLoS One 2010; 5(10): e13737. doi: 10.1371/journal.pone.0013737 PMID: 21060835
  13. Zhang F, Wang Y, Wang J. Handbook of China's free ART program. Cell Research 2012; 15: 877-82.
  14. Xu Q, Guo H, Jin Y, et al. Advantages of chinese medicine for patients with acquired immunodeficiency syndrome in rural central china. Chin J Integr Med 2018; 24(12): 891-6. doi: 10.1007/s11655-017-2418-8 PMID: 28887810
  15. Jin Y, Zhang M, Ma Y, et al. Effects of chinese medicine on the survival of aids patients administered second-line ART in rural areas of china: A retrospective cohort study based on real-world data. Evid Based Complement Alternat Med 2022; 2022: 5103768. doi: 10.1155/2022/5103768
  16. Jin Y, Meng X, Liu S, et al. Prevalence trend and risk factors for anemia among patients with human immunodeficiency virus infection receiving antiretroviral therapy in rural China. J Tradit Chin Med 2019; 39(1): 111-7.
  17. Liang Y, Yang W J, Sun D Y, et al. Survival analysis on former plasma donors living with HIV/AIDS after initiation of antiretroviral therapy in Henan province. Zhonghua Liu Xing Bing Xue Za Zhi 2019; 40(6): 638-42. doi: 10.3760/cma.j.issn.0254-6450.2019.06.007
  18. Zhu J, Gao R, Zhao S, et al. Chinese guidelines for prevention and treatment of dyslipidemia in adults (2016 Revision). Chin J Circulat 2016; 31(10): 937-53.
  19. Tsung I, Dolan R, Lao CD, et al. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. Aliment Pharmacol Ther 2019; 50(7): 800-8. doi: 10.1111/apt.15413 PMID: 31309615
  20. Hematology Branch of Chinese Medical Association. Multidisciplinary expert consensus on the diagnosis, treatment and prevention of iron deficiency and iron deficiency anemia (2022 edition). Chin Med J 2022; 102(41): 3246-56. J. doi: 10.3760/cma.j.cn112137-20220621-01361
  21. Cao W J, Yao Y M, Wei W, et al. Survival time and related factors on HIV/AIDS patients in Guizhou province from 1995 to 2018. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41(4): 557-61. doi: 10.3760/cma.j.cn112338-20190604-00395
  22. Tsegaye AT, Alemu W, Ayele TA. Incidence and determinants of mortality among adult HIV infected patients on second-line antiretroviral treatment in Amhara region, Ethiopia: a retrospective follow up study. Pan Afr Med J 2019; 33: 89. doi: 10.11604/pamj.2019.33.89.16626 PMID: 31489067
  23. Gao D, Zou Z, Dong B, et al. Secular trends in HIV/AIDS mortality in China from 1990 to 2016: Gender disparities. PLoS One 2019; 14(7): e0219689. doi: 10.1371/journal.pone.0219689 PMID: 31318900
  24. Mangal TD, Meireles MV, Pascom ARP, de Almeida Coelho R, Benzaken AS, Hallett TB. Determinants of survival of people living with HIV/AIDS on antiretroviral therapy in Brazil 2006–2015. BMC Infect Dis 2019; 19(1): 206. doi: 10.1186/s12879-019-3844-3 PMID: 30819120
  25. Zhu K, Xu Q, Ma Y, et al. Suboptimal immune recovery and associated factors among people living with HIV/AIDS on second-line antiretroviral therapy in central China: A retrospective cohort study. J Med Virol 2022; 94(10): 4975-82. doi: 10.1002/jmv.27944 PMID: 35710693
  26. Ahn MY, Jiamsakul A, Khusuwan S, et al. The influence of age-associated comorbidities on responses to combination antiretroviral therapy in older people living with HIV. J Int AIDS Soc 2019; 22(2): e25228. doi: 10.1002/jia2.25228 PMID: 30803162
  27. Ross J, Jiamsakul A, Kumarasamy N, et al. Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific. HIV Med 2020; 22(3): 201-11. doi: 10.1111/hiv.13006 PMID: 33151020
  28. Marchionatti A, Parisi MM. Anemia and thrombocytopenia in people living with HIV/AIDS: A narrative literature review. Int Health 2021; 13(2): 98-109. doi: 10.1093/inthealth/ihaa036 PMID: 32623456
  29. Deressa T, Damtie D, Workineh M, Genetu M, Melku M. Anemia and thrombocytopenia in the cohort of HIV-infected adults in northwest Ethiopia: A facility-based cross-sectional study. EJIFCC 2018; 29(1): 36-47. PMID: 29765285
  30. Nigussie F, Alamer A, Mengistu Z, Tachbele E. Survival and predictors of mortality among adult HIV/AIDS patients initiating highly active antiretroviral therapy in debre-berhan referral hospital, amhara, ethiopia: A retrospective study. HIV AIDS 2020; 12: 757-68. doi: 10.2147/HIV.S274747 PMID: 33239921
  31. Verna EC. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. Lancet Gastroenterol Hepatol 2017; 2(3): 211-23. doi: 10.1016/S2468-1253(16)30120-0 PMID: 28404136
  32. Taborelli M, Suligoi B, Toffolutti F, et al. Excess liver-related mortality among people with AIDS compared to the general population: An Italian nationwide cohort study using multiple causes of death. HIV Med 2020; 21(10): 642-9. doi: 10.1111/hiv.12937 PMID: 32876382
  33. Jin Y, Wang X, Li Z, et al. Survival of AIDS patients treated with traditional chinese medicine in rural central china: A retrospective cohort study, 2004-2012. Evid Based Complement Alternat Med 2015; 2015: 1-7. doi: 10.1155/2015/282819 PMID: 25821482
  34. Wang Y, Jin F, Wang Q, et al. Long-term survival of AIDS patients treated with only traditional chinese medicine. Altern Complement Ther 2017; 23(2): 60-2. doi: 10.1089/act.2017.29106.ywa
  35. Li X, Li H, Li C, Xia W, Li A, Li W. Traditional chinese medicine can improve the immune reconstruction of HIV/AIDS patients. AIDS Res Hum Retroviruses 2020; 36(4): 258-9. doi: 10.1089/aid.2019.0274 PMID: 31958968
  36. Wang D, Ma S, Ma Y, et al. Effect of traditional chinese medicine therapy on the trend in CD4+ T-Cell counts among patients with HIV/AIDS treated with antiretroviral therapy: A retrospective cohort study. Evid Based Complement Alternat Med 2021; 2021: 5576612. doi: 10.1155/2021/5576612

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers